Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
Company Details
- Employees
- 33
- Address
- Munich, Munich,germany
- Industry
- Biotechnology
- Website
- https://complementtx.com/
- Keywords
- Manager..
- HQ
- Munich
Complement Therapeutics Questions
Complement Therapeutics's website is https://complementtx.com/
Complement Therapeutics's LinkedIn profile is https://www.linkedin.com/company/complement-therapeutics
Complement Therapeutics has
33 employees.
View email and phone details for 33
employees at Complement Therapeutics.
Complement Therapeutics's industry is
Biotechnology
Complement Therapeutics's top competitors are
Aavantgarde,
Glycomine Inc.,
Beacon Therapeutics,
Resolution Therapeutics,
Aviadobio,
Opthea,
Touchlight,
Cell And Gene Therapy Catapult,
Pharmaron Biologics And Cell & Gene Therapy,
Meiragtx.
Complement Therapeutics's categories are Biotechnology
